Physician profile
Keith Bonacquisti
NPI 1487773669
$3,362.71
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $1,163 · 2021: $675 · 2022: $455 · 2023: $384 · 2024: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $724.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $771.39 | 2020 | |
| Intersect Ent, INC. | $525.55 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $457.85 | 2021-2024 | Dupixent, Libtayo |
| Optinose US, INC. | $329.06 | 2021-2024 | |
| Glaxosmithkline, LLC. | $299.68 | 2021-2024 | Nucala |
| Acclarent, INC | $227.30 | 2019-2023 | Acclarent Aera |
| Karl Storz Endoscopy-America | $198.87 | 2021-2022 | |
| Genzyme Corporation | $187.50 | 2020-2024 | |
| Stryker Corporation | $147.18 | 2019-2021 | |
| Amgen INC. | $77.51 | 2020 | |
| Cochlear Americas | $63.38 | 2021 | |
| Sanofi-Aventis U.S. LLC | $29.00 | 2021 | |
| Smith+Nephew, INC. | $24.45 | 2019-2022 | |
| Olympus America INC. | $23.99 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Bonacquisti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.